McKesson (MCK) Could Be 4% Undervalued After Renewing CVS Deal Through 2032

McKesson (MCK) has been in focus after renewing its pharmaceutical distribution partnership with CVS Health through June 2032, a long dated agreement that helps clarify visibility on a key customer relationship.

Investor attention has lined up with these contract updates, with McKesson’s share price gaining 16.49% over the past 90 days and 5.29% over the past month. The 1 year total shareholder return of 23.44% and 5 year total shareholder return of roughly 4.7x indicate that momentum has been firmly positive over both shorter and longer horizons.

Scan how McKesson’s renewed CVS agreement compares with other distributors by reviewing a hand picked set of list of solid balance sheet and fundamentals (25 results).

McKesson now pairs a long dated CVS contract with a share price that has already moved hard in anticipation. The question is whether this is still a solid business at a fair tag, or a strong business at a stretched one.

Most Popular Narrative: 4% Undervalued

McKesson’s most followed thesis points to a fair value of $980.73 based on a 7.24% discount rate, compared with the latest close at $938.84. This frames the recent price strength as still leaving a valuation gap on the table.

Disciplined capital deployment, including the planned US$2.25b Precision Medicine Group acquisition, the minority investment and targeted 2027 IPO of Wellverse, and an intention to allocate about US$5b to share repurchases alongside higher dividends, is set up to influence earnings per share growth and returns on equity.

See why 61 investors see McKesson as 4% undervalued.

Result: Fair Value of $980.73 (UNDERVALUED)

Still, the McKesson story can break if regulatory pressure on drug pricing tightens further or if cyber incident fallout meaningfully erodes customer trust and margins.

Find out about the key risks to this McKesson narrative.

Next Steps

If this mix of optimism and concern around McKesson leaves you on the fence, move quickly to study the details and shape your own take using 4 key rewards and 1 important warning sign.

Looking for more McKesson sized investment ideas?

Before you log off, put McKesson in context by lining it up against fresh stock ideas sourced from focused screeners built to surface specific strengths.

• Target resilience first and stress test your portfolio against shocks by scanning a 31 resilient stocks with low risk scores that keeps downside firmly in view.
• Hunt for quality at a sensible tag by filtering through a 28 high quality undervalued stocks that blends fundamentals with pricing discipline.
• Spot potential future leaders early by combing through a 20 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com